Hq Specialty Pharma
As of the edition of 20 October 2026, Hq Specialty Pharma runs 11 drugs, 11 of them marketed; it is on route A at 0 targets and on route B at 2 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 11 |
| Total | 11 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Paclitaxel | none listed | 0 |
| Cisplatin | none listed | 0 |
| Dexmedetomidine | none listed | 9 |
| Levetiracetam | none listed | 3 |
| Meropenem | none listed | 0 |
| Calcium | none listed | 0 |
| Cefazolin | none listed | 0 |
| Diltiazem | none listed | 8 |
| Esmolol | none listed | 1 |
| Calcium gluconate | none listed | 0 |
| Teniposide | none listed | 3 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 2 targets.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where Hq Specialty Pharma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.